Switch theme
Sign up to access all valuation multiples
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
2015
110
LTM Revenue $30.3M
LTM EBITDA -$110M
-$62.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
C4 Therapeutics has a last 12-month revenue (LTM) of $30.3M and a last 12-month EBITDA of -$110M.
In the most recent fiscal year, C4 Therapeutics achieved revenue of $35.6M and an EBITDA of -$103M.
C4 Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See C4 Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $30.3M | XXX | $35.6M | XXX | XXX | XXX |
| Gross Profit | $30.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$110M | XXX | -$103M | XXX | XXX | XXX |
| EBITDA Margin | -365% | XXX | -290% | XXX | XXX | XXX |
| EBIT | -$120M | XXX | -$117M | XXX | XXX | XXX |
| EBIT Margin | -395% | XXX | -329% | XXX | XXX | XXX |
| Net Profit | -$113M | XXX | -$105M | XXX | XXX | XXX |
| Net Margin | -372% | XXX | -296% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, C4 Therapeutics's stock price is $1.
C4 Therapeutics has current market cap of $88.8M, and EV of -$62.0M.
See C4 Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$62.0M | $88.8M | XXX | XXX | XXX | XXX | $-1.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, C4 Therapeutics has market cap of $88.8M and EV of -$62.0M.
C4 Therapeutics's trades at -1.7x EV/Revenue multiple, and 0.6x EV/EBITDA.
Equity research analysts estimate C4 Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
C4 Therapeutics has a P/E ratio of -0.8x.
See valuation multiples for C4 Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $88.8M | XXX | $88.8M | XXX | XXX | XXX |
| EV (current) | -$62.0M | XXX | -$62.0M | XXX | XXX | XXX |
| EV/Revenue | -2.0x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | -2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.8x | XXX | -0.8x | XXX | XXX | XXX |
| EV/FCF | 0.6x | XXX | 0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialC4 Therapeutics's last 12 month revenue growth is -26%
C4 Therapeutics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.4M for the same period.
C4 Therapeutics's rule of 40 is -643% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
C4 Therapeutics's rule of X is -431% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for C4 Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -26% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -365% | XXX | -290% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | -643% | XXX | -317% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -431% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 311% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 429% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
C4 Therapeutics acquired XXX companies to date.
Last acquisition by C4 Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . C4 Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was C4 Therapeutics founded? | C4 Therapeutics was founded in 2015. |
| Where is C4 Therapeutics headquartered? | C4 Therapeutics is headquartered in United States of America. |
| How many employees does C4 Therapeutics have? | As of today, C4 Therapeutics has 110 employees. |
| Who is the CEO of C4 Therapeutics? | C4 Therapeutics's CEO is Mr. Andrew J. Hirsch. |
| Is C4 Therapeutics publicy listed? | Yes, C4 Therapeutics is a public company listed on NAS. |
| What is the stock symbol of C4 Therapeutics? | C4 Therapeutics trades under CCCC ticker. |
| When did C4 Therapeutics go public? | C4 Therapeutics went public in 2020. |
| Who are competitors of C4 Therapeutics? | Similar companies to C4 Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of C4 Therapeutics? | C4 Therapeutics's current market cap is $88.8M |
| What is the current revenue of C4 Therapeutics? | C4 Therapeutics's last 12 months revenue is $30.3M. |
| What is the current revenue growth of C4 Therapeutics? | C4 Therapeutics revenue growth (NTM/LTM) is -26%. |
| What is the current EV/Revenue multiple of C4 Therapeutics? | Current revenue multiple of C4 Therapeutics is -2.0x. |
| Is C4 Therapeutics profitable? | Yes, C4 Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of C4 Therapeutics? | C4 Therapeutics's last 12 months EBITDA is -$110M. |
| What is C4 Therapeutics's EBITDA margin? | C4 Therapeutics's last 12 months EBITDA margin is -365%. |
| What is the current EV/EBITDA multiple of C4 Therapeutics? | Current EBITDA multiple of C4 Therapeutics is 0.6x. |
| What is the current FCF of C4 Therapeutics? | C4 Therapeutics's last 12 months FCF is -$99.4M. |
| What is C4 Therapeutics's FCF margin? | C4 Therapeutics's last 12 months FCF margin is -329%. |
| What is the current EV/FCF multiple of C4 Therapeutics? | Current FCF multiple of C4 Therapeutics is 0.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
